ELEVATION ONCOLOGY INC (ELEV)
US28623U1016 - Common Stock
ChartMill assigns a Buy % Consensus number of 85% to ELEV. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 7.91. This target is 113.65% above the current price.
ELEV was analyzed by 11 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about ELEV.
In the previous month the buy percentage consensus was at a similar level.
ELEV was analyzed by 11 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-05-03 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-04-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-07 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-03-07 | Wedbush | Maintains | Outperform -> Outperform |
| 2024-03-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-01 | JMP Securities | Initiate | Market Outperform |
| 2024-02-20 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-06 | Wedbush | Reiterate | Outperform -> Outperform |
| 2023-09-29 | HC Wainwright & Co. | Initiate | Buy |
| 2023-06-05 | Wedbush | Maintains | Outperform -> Outperform |
| 2023-05-30 | SVB Securities | Upgrade | Market Perform -> Outperform |
| 2023-03-10 | Wedbush | Reiterate | Outperform |
| 2023-01-09 | SVB Leerink | Maintains | Market Perform |
| 2022-11-10 | JP Morgan | Downgrade | Neutral -> Underweight |
| 2022-11-07 | SVB Leerink | Downgrade | Outperform -> Market Perform |
| 2022-08-08 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2022-03-04 | Wedbush | Maintains | Outperform |
| 2021-12-23 | HC Wainwright & Co. | Initiate | Buy |
| 2021-07-20 | SVB Leerink | Initiate | Outperform |
| 2021-07-20 | Cowen & Co. | Initiate | Outperform |
| 2021-07-20 | Wedbush | Initiate | Outperform |